Lung Cancer Clinical Trial
Official title:
Cohort Studies of Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer, Including Non-small-cell Lung Cancer and Small-cell Lung Cancer With Early and Advanced Staging (STRESS-LUNG)
This is the prospective, observational cohort study (STRESS-LUNG) to explore the associations of psychological stress with progression, efficacy of immune checkpoint inhibitors (ICIs) and prognosis of Lung Cancer. The participants including the patients diagnosed with advanced non-small-cell lung cancer (NSCLC) who received the first-line therapy or neoadjuvant therapy of ICIs; patients diagnosed with advanced small-cell lung cancer (SCLC) receiving the first-line therapy ICIs; patients diagnosed with early small-cell lung cancer (SCLC) receiving surgery.
Status | Recruiting |
Enrollment | 750 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Cohort 1 (STRESS-LUNG-1): Inclusion Criteria: 1. Age = 18 years; 2. Histologically confirmed diagnosis of NSCLC; 3. Unresectable locally advanced, metastatic, or recurrent stage ?B-? based on AJCC TNM staging 8th edition; 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy ); 6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ; 7. Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy; 8. Informed and agreed to participate in the study; Exclusion Criteria: 1. Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) gene and/or ROS proto-oncogene 1 (ROS1) fusion-positive; 2. Combined with other malignant tumors in the past 3 years; 3. Concurrent acute or chronic psychiatric disorders; 4. Current receiving anti-depressive or anti-anxiety therapy; 5. Previous treatment with other clinical drug trials; 6. Patients with symptomatic brain metastasis; 7. Can't cooperate with psychological scale assessment; Cohort 2 (STRESS-LUNG-2): 1. Age = 18 years; 2. Pathologically diagnosed as small cell lung cancer; 3. Unresectable locally advanced, metastatic, or recurrent stage ?-? based on AJCC TNM staging 8th edition; 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy ); 6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ; 7. Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy; 8. Informed and agreed to participate in the study; Exclusion Criteria: 1. Combined with other malignant tumors in the past 3 years; 2. Concurrent acute or chronic psychiatric disorders; 3. Current receiving anti-depressive or anti-anxiety therapy; 4. Previous treatment with other clinical drug trials; 5. Patients with symptomatic brain metastasis; 6. Can't cooperate with psychological scale assessment; Cohort 3 (STRESS-LUNG-3): 1. Age =18 years ; 2. Pathologically diagnosed as non-small cell lung cancer; 3. Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition; 4. At least one measurable lesion can be evaluated according to the RECIST 1.1 standard; 5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy ); 6. Receiving PD-1/PD-L1 inhibitors combined with chemotherapy as neoadjuvant therapy. 6. Cardiopulmonary function can withstand surgery; 7. Informed and agreed to participate in the study; Exclusion Criteria: 1. Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) gene and/or ROS proto-oncogene 1 (ROS1) fusion-positive; 2. Combined with other malignant tumors in the past 3 years; 3. Concurrent acute or chronic psychiatric disorders; 4. Current receiving anti-depressive or anti-anxiety therapy; 5. Previous treatment with other clinical drug trials; 6. Can't cooperate with psychological scale assessment; Cohort 4 (STRESS-LUNG-4): 1. Age =18 years; 2. Pathologically diagnosed as non-small-cell lung cancer; 3. Pathologically stage conformed as early stage of IA-IIIA 4. Available for tumor tissue samples; 5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy ); 6. Receiving radical surgery; 7. Informed and agreed to participate in the study; Exclusion Criteria: 1. Combined with other malignant tumors in the past 3 years; 2. Concurrent acute or chronic psychiatric disorders; 3. Current receiving anti-depressive or anti-anxiety therapy; 4. Previous treatment with other clinical drug trials; 5. Can't cooperate with psychological scale assessment; |
Country | Name | City | State |
---|---|---|---|
China | Department of Oncology, The Second Xiangya Hospital, Central South University | Changsha | Hunan |
Lead Sponsor | Collaborator |
---|---|
Second Xiangya Hospital of Central South University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | The correlation between gut microbiota and chronic stress and the efficacy of ICIs | The baseline fetal is collected and assessed by 16S rRNA sequencing. And explore the association between gut microbiota and chronic stress and the efficacy of ICIs during the enrolled observation process. | 5 years | |
Other | The correlation between tumor microenvironment signature and chronic stress and the efficacy of ICIs | The baseline paraffin-embedded tissue is collected and assessed by multiplex immunohistochemistry, including T lymphocytes, B lymphocytes, NK lymphocytes, macrophagocyte, and DC cells. And explore the association between tumor microenvironment signature and chronic stress and the efficacy of ICIs during the enrolled observation process. | 5 years | |
Other | The correlation between peripheral stress biomarker and immune cells signature and chronic stress and the efficacy of ICIs | The baseline peripheral venous blood is collected. The stress biomarkers including epinephrine, norepinephrine, cortisol and ACTH. The peripheral immune cells signature and assessed by flow cytometry, including T lymphocytes, B lymphocytes, NK lymphocytes, macrophagocyte, and DC cells. | 5 years | |
Primary | Cohort 1 & 2: Progression-free survival (PFS) | Time from the beginning of first-line immunotherapy to the first progression (PD) in patients with lung cancer | 3 years | |
Primary | Cohort 3: Pathologic complete response (pCR) rate | pCR is no viable tumor cells in tumor bed and lymph nodes. The pCR rate is the proportion of patients with a pathologic complete response. | 3 years | |
Primary | Cohort 4: Disease-free survival (DFS) | The duration between the date after surgery to the date of any recurrence or death firstly | 5 years | |
Secondary | Overall survival (OS) | Overall survival (OS) is defined as the duration from the beginning of first-line immunotherapy until death due to any cause. Subjects who are still alive at the end of the study observation period will be censored at the time of last known vital status. | 5 years | |
Secondary | Quality of life | Quality of life (QoL) is assessed longitude by Short Form Health Survey 36 (SF-36) and EORTC QLQ-C30 (version.3).
SF-36 includes 36 items and assesses the functional status and well-being on eight multi-item subscales. The total score on each SF-36 subscale ranges between 0 and 100. A greater score indicates better QoL. The EORTC QLQ-C30 is composed of 9 multi-item scales: 5 functioning scales (physical, role, cognitive, emotional, and social), a global QOL scale, and 3 symptom scales (fatigue, pain, and nausea/vomiting). All scales and single items are linearly transformed to an 0-100 scale. A higher score represents a better level of functioning. |
5 years | |
Secondary | Objective Response Rate (ORR) | The proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|